The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Carhart-Harris, Robin L, Goodwin, Guy M·2017·Neuropsychopharmacology
DOI 10.1038/npp.2017.84

Cited by (702)

Items 201–300 of 702

  1. Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
    Mikkel Højlund, Helin Yılmaz Kafalı, Begüm Kırmızı, Paolo Fusar‐Poli, Christoph Ulrich Correll, Samuele Cortese, Michel Sabé, Jess G. Fiedorowicz, Gayatri Saraf, Josephine Zein et al. · 2025 · European Neuropsychopharmacology
  2. Depression as a Disorder of Consciousness
    Cecily M. K. Whiteley · 2021 · The British Journal for the Philosophy of Science
  3. Reduced death anxiety and obsessive beliefs as mediators of the therapeutic effects of psychedelics on obsessive compulsive disorder symptomology
    Sam G. Moreton, Amber Burden-Hill, Rachel E. Menzies · 2022 · Clinical Psychologist
  4. Ketamine: Quo Vadis?
    Nemeroff, Charles B. · 2018 · American Journal of Psychiatry
  5. Will psilocybin lose its magic in the clinical setting?
    Caroline Hayes, Mourad Wahba, Stuart Watson · 2022 · Therapeutic Advances in Psychopharmacology
  6. Reduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics
    Devon Stoliker, Gary F. Egan, Adeel Razi · 2022 · Frontiers in Neuroscience
  7. Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice
    Lauri V. Elsilä, Juliana Harkki, E. Enberg, Alvar Martti, Anni-Maija Linden, Esa R. Korpi · 2022 · Journal of Psychopharmacology
  8. Flicker light stimulation enhances the emotional response to music: a comparison study to the effects of psychedelics
    Caspar Montgomery, Ioanna Alicia Amaya, Timo Torsten Schmidt · 2024 · Frontiers in Psychology
  9. Opportunities in Novel Psychotropic Drug Design from Natural Compounds
    Siu Wa Tang, Wayne H. Tang · 2019 · The International Journal of Neuropsychopharmacology
  10. Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
    Shakila Meshkat, Gunjan Malik, Richard J. Zeifman, Jennifer Swainson, Krishna Balachandra, Amy Claire Reichelt, Yanbo Zhang, Lisa Burback, Olga Winkler, Andrew James Greenshaw et al. · 2025 · Neuroscience & Biobehavioral Reviews
  11. The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
    Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, Oana Albai, Laura Alexandra Nussbaum, Adriana Cojocaru, Leonardo Corsaro, Teodora Anghel · 2025 · Medicina
  12. Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review
    Clémentine Estric, Thomas Duron, Sarah Kabani, Jorge López‐Castromán · 2025 · Journal of Psychopharmacology
  13. The psychedelic ritual as a technique of the self
    David Dupuis · 2022 · Hau Journal of Ethnographic Theory
  14. Psychedelics and disorders of consciousness: the current landscape and the path forward
    Paolo Cardone, Naji Alnagger, Jitka Annen, Aminata Bicego, Olivia Gosseries, Charlotte Martial · 2024 · Neuroscience of Consciousness
  15. Red visual stimulation in theGanzfeldleads to a relative overestimation of duration compared to green
    Sebastian L. Kübel, Henrike Fiedler, Marc Wittmann · 2020 · PsyCh Journal
  16. Out of the box: A psychedelic model to study the creative mind
    Kim P. C. Kuypers · 2018 · Medical Hypotheses
  17. The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis
    Elena Argento, Kenneth W. Tupper, Maria Eugenia Socias · 2019 · International Journal of Drug Policy
  18. Neural and subjective effects of inhaled DMT in natural settings
    Carla Pallavicini, Federico Cavanna, Federico Zamberlán, Laura Alethia de la Fuente, Yonatan Sanz Perl, Mauricio Arias, Celeste Romero, Robin Lester Carhart-Harris, Christopher Timmermann, Enzo Tagliazucchi · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  19. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
    Gill, Hartej, Puramat, Parnian, Patel, Pankti, Gill, Barjot, Marks, CéAnn A., Rodrigues, Nelson B., Castle, David, Cha, Danielle S., Mansur, Rodrigo B., Rosenblat, Joshua Daniel et al. · 2022 · Psychiatry Research
  20. Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders
    Nataliya S. Vorobyeva, Alena A. Kozlova · 2022 · Frontiers in Pharmacology
  21. Investigating the relationship between changes in metaphysical beliefs and death anxiety following a significant psychedelic experience
    Sam G. Moreton, N. Barr, Kayla J. Giese · 2024 · Death Studies
  22. Bridging the gap between single receptor type activity and whole‐brain dynamics
    Dirk Jancke, Stefan Herlitze, Morten L. Kringelbach, Gustavo Deco · 2021 · FEBS Journal
  23. Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders
    Brian J. Lopresti, Sarah K. Royse, Chester A. Mathis, Savannah Tollefson, Rajesh Narendran · 2022 · Journal of Neurochemistry
  24. IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain
    Eda Köşeli, Belle Buzzi, Torin Honaker, Yogesh Rakholia, Melissa Lewis, Maya Gaines-Smith, Alaina M. Jaster, Javier González‐Maeso, Mohamad Imad Damaj · 2025 · Pharmacological Research
  25. Blinding Integrity in Psychedelic Randomized Clinical Trials
    Diana K. Orsini, Sabrina Wong, Sara D Di Luch, Brendan Chan, Shreya Vasudeva, Gabrielle F. M. Lovell, Gia Han Le, Brett D. M. Jones, Noah Chisamore, Adriano Mollica et al. · 2026 · JAMA Psychiatry
  26. The selective 5-HT2A receptor agonist 25CN-NBOH does not affect reversal learning in mice
    Anna U. Odland, Jesper Langgaard Kristensen, Jesper Tobias Andreasen · 2021 · Behavioural Pharmacology
  27. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology
    Daniel F. Kelly, Keith G. Heinzerling, Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi, Regin Jay Mallari · 2022 · Neurosurgery
  28. A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
    Alexander R. Pilozzi, Simmie L. Foster, David Mischoulon, Maurizio Fava M. D, Xudong Huang · 2023 · International Journal of Molecular Sciences
  29. Psychedelics and schizophrenia: a double-edged sword
    Jacopo Sapienza, Francesca Martini, Stefano Comai, Roberto Cavallaro, Marco Spangaro, Danilo De Gregorio, Marta Bosia · 2024 · Molecular Psychiatry
  30. Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis
    Mattia Marchi, Riccardo Farina, Karim Rachedi, Francesca Laonigro, Marija Franka Žuljević, Luca Pingani, Sílvia Ferrari, Metten Somers, Marco P. Boks, Gian Maria Galeazzi · 2024 · Journal of Psychopharmacology
  31. Bis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocin
    A.R. Chadeayne, Duyen N. K. Pham, James A. Golen, David R. Manke · 2020 · Acta Crystallographica Section E Crystallographic Communications
  32. Psychedelic drugs in the treatment of anxiety, depression and addiction
    Tor-Morten Kvam, Lowan Han Stewart, Ole A. Andreassen · 2018 · Tidsskrift for Den norske legeforening
  33. Norpsilocin: freebase and fumarate salt
    A.R. Chadeayne, Duyen N. K. Pham, James A. Golen, David R. Manke · 2020 · Acta Crystallographica Section E Crystallographic Communications
  34. Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA
    Jay B. Nair, Linda B Hakes, Berra Yazar‐Klosinski, Kathryn Paisner · 2021 · ACS Omega
  35. Demystifying hypnosis: Unravelling facts, exploring the historical roots of myths, and discerning what is hypnosis
    Dali Geagea, David Ogez, Roy Mark Kimble, Zephanie F. Tyack · 2023 · Complementary Therapies in Clinical Practice
  36. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder
    Mario Renato Velit-Salazar, Paulo R. Shiroma, Eloise Cherian · 2024 · Brain Sciences
  37. The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin
    Utkirjon Holikulov, Аleksandr S. Kazachenko, Noureddine Issaoui, Анна Семеновна Казаченко, Murugesan Raja, Omar Marzook Al-Dossary, Zhouyang Xiang · 2024 · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy
  38. Cannabis‐infused foods: Phytonutrients, health, and safe product innovations
    Eric Fordjour, Charles F. Manful, Tarsaim S. K. Khalsamehta, Abraham Armah, Mumtaz Cheema, Raymond Thomas · 2024 · Comprehensive Reviews in Food Science and Food Safety
  39. Training the embodied self in its impermanence: meditators evidence neurophysiological markers of death acceptance
    Yair Dor‐Ziderman, Yoav Schweitzer, Ohad Nave, Fynn‐Mathis Trautwein, Stephen John Fulder, Antoine Lutz A, Abraham Goldstein, Aviva Berkovich‐Ohana · 2025 · Neuroscience of Consciousness
  40. The serotonin 2A receptor agonist TCB‐2 attenuates heavy alcohol drinking and alcohol‐induced midbrain inhibitory plasticity
    Blake A. Kimmey, Ruthie E. Wittenberg, Alexandra Croicu, Nikita Shadani, Alexey Ostroumov, John A. Dani · 2022 · Addiction Biology
  41. Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial
    Vanderijst, Laetitia, Hever, Felix, Buot, Anne, Dauré, Charles, Benoit, Janaïna, Hanak, Catherine, Veeser, Johannes, Morgiève, Margot, Campanella, Salvatore, Kornreich, Charles et al. · 2024 · BMC Psychiatry
  42. A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe
    Raphaël Serreau, Ammar Amirouche, Amine Benyamina, Sabine Berteina‐Raboin · 2022 · Pharmaceuticals
  43. Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States
    Stacey B. Armstrong, Adam W. Levin, Yitong Xin, Jordan Horan, Jason B. Luoma, Paul B. Nagib, Brian C. Pilecki, Alan K. Davis · 2023 · Journal of Psychedelic Studies
  44. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
    Francisco Madrid-Gambín, David Fabregat‐Safont, Àlex Gomez‐Gómez, Eulàlia Olesti, Natasha Leigh Mason, Johannes Gerardus Ramaekers, Óscar J. Pozo · 2023 · Biomedicine & Pharmacotherapy
  45. Dose-dependent LSD effects on cortical/thalamic and cerebellar activity: brain oxygen level–dependent fMRI study in awake rats
    Ashley Ghaw, Alisha Chunduri, Arnold Chang, Richard J. Ortiz, Milena Kozlowska, Praveen P Kulkarni, Craig F. Ferris · 2024 · Brain Communications
  46. History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers
    Michaela Barber, John Gardner, Adrian Carter · 2024 · Journal of Bioethical Inquiry
  47. 5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity
    Christopher B. Germann · 2019 · Activitas Nervosa Superior
  48. Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence
    Elena Koning, Elisa Macedo Brietzke · 2023 · Trends in Psychiatry and Psychotherapy
  49. Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts
    Natasha Leigh Mason, Patrick C. Dolder, Kim P. C. Kuypers · 2020 · Drug Science Policy and Law
  50. Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis
    Haley D.M. Schuman, Chantal Savard, Raèf Mina, Sofia Barkova, Hanna S. W. Conradi, Julie M. Deleemans, Linda E. Carlson · 2025 · Current Oncology
  51. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees
    William L. Prueitt, Jordan Sloshower · 2022 · Academic Psychiatry
  52. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
    Rebecca S. Ryan, Alex G. Copello, Andrew P. Fox · 2023 · BMC Psychiatry
  53. On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy
    Nadav Liam Modlin, Joanne Stubley, Carolina Maggio, James Rucker · 2023 · British Journal of Psychotherapy
  54. Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial
    Shakila Meshkat, Richard J. Zeifman, Kathleen E. Stewart, Reinhard Janssen‐Aguilar, Wendy Y. W. Lou, Rakesh Jetly, Candice M. Monson, Venkat Bhat · 2025 · PLoS ONE
  55. Subject in the Making: Technologies of the Self and Aspirations for a Good Life in Contemporary Denmark
    Margit Anne Petersen, Aja Smith, Dorthe Brogård Kristensen, Klaus Hoeyer · 2022 · Medical Anthropology
  56. The fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocin
    A.R. Chadeayne, Duyen N. K. Pham, James A. Golen, David R. Manke · 2019 · Acta Crystallographica Section E Crystallographic Communications
  57. Microdosing psychedelics as cognitive and emotional enhancers.
    Ben David Rifkin, María J. Maraver, Lorenza S. Colzato · 2020 · Psychology of Consciousness Theory Research and Practice
  58. Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice
    Błażej D. Pędzich, Mireia Medrano, An Buckinx, Ilse Julia Smolders, Dimitri De Bundel · 2022 · International Journal of Molecular Sciences
  59. Psilocybin in pharmacotherapy of obsessive-compulsive disorder
    Maja Owe-Larsson, Katarzyna Kamińska, Barbara Buchalska, Dagmara Maria Mirowska-Guzel, Agnieszka Cudnoch‐Jędrzejewska · 2024 · Pharmacological Reports
  60. Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study
    Marija Franka Žuljević, Darko Hren, Dawid Storman, Mariano Kaliterna, Darko Duplančić · 2024 · Scientific Reports
  61. Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder
    Claire Miller, Phillip R. Zoladz · 2024 · Journal of Pharmacology and Experimental Therapeutics
  62. Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use
    Omer A. Syed, Rotem Petranker, Emily C. Fewster, Valentyne Sobolenko, Zeina Beidas, Muhammad Ishrat Husain, Stephanie Lake, Philippe Lucas · 2024 · Journal of Psychoactive Drugs
  63. Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions
    Timon Elmer, Tanya K. Vannoy, Erich Studerus, Sonja Lyubomirsky · 2024 · Scientific Reports
  64. Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
    Dominique Denis-Lalonde, Andrew Estefan · 2020 · Journal of Mental Health and Addiction Nursing
  65. Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers
    Juliana Marino Maia, Bruna Stefane Alves de Oliveira, Luiz G.S. Branco, Renato Nery Soriano · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  66. Modulation of serotonin transporter expression by escitalopram under inflammation
    Sergio Mena, Allison Cruikshank, Janet A. Best, H. Frederik Nijhout, Michael C. Reed, Parastoo Hashemi · 2024 · Communications Biology
  67. Classic psychedelics and the treatment for alcoholism
    Guilherme Lodetti, Rafael Mariano de Bitencourt, Eduardo Pacheco Rico · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  68. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
    Petros D. Petridis, Jack Grinband, Gabrielle Agin-Liebes, Connor Jarrett Kinslow, Richard J. Zeifman, Michael P. Bogenschutz, Roland R. Griffiths, Stephen Ross · 2024 · Nature Mental Health
  69. Fragile promise of psychedelics in psychiatry
    Lemarchand, Cédric, Chopin, Raphaël, Paul, Morgane, Braillon, Alain, Cosgrove, Lisa, Cristea, Ioana, Fried, Eiko I, Turner, Erick H, Naudet, Florian · 2024 · BMJ
  70. The ketamine chameleon: history, pharmacology, and the contested value of experience
    Danny Diep, Sara de la Salle, Julien Thibault Lévesque, Michael Lifshitz, Nicolas Garel, Kyle T. Greenway · 2025 · Expert Review of Clinical Pharmacology
  71. Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action
    Jonathan Repple, Maximilian Bayas, Chiara Möser, Nene F. Kobayashi, Andreas Reif · 2025 · Biological Psychiatry
  72. Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View
    Naser‐Aldin Lashgari, Mahla Khalaji, Pouria Rana, Fatemeh Badrabadi, Mobina Rahnama, Hadis Nasoori, Nazanin Momeni Roudsari, Mohammad Mahdi Khosravi Nia, Hamed Shafaroodi · 2025 · Molecular Neurobiology
  73. The regulation project: Tools for engaging the public in the legal regulation of drugs
    Scott E. Bernstein, Emily Amirkhani, Dan Werb, Donald MacPherson · 2020 · International Journal of Drug Policy
  74. Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy
    Héctor Vargas-Pérez, Taryn Elizabeth Grieder, Derek van der Kooy · 2022 · Journal of Psychoactive Drugs
  75. Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica
    Maria Orozco, Shana Harris · 2022 · Anthropology of Consciousness
  76. Towards a phenomenological approach to psychopharmacology: drug-centered model and epistemic empowerment
    Marcelo Lopes, Guilherme Peres Messas · 2023 · Phenomenology and the Cognitive Sciences
  77. UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study
    Charlie Song-Smith, Edward Jacobs, James Rucker, Matthew Saint, James E. Cooke, Marco Schlosser · 2024 · BMJ Open
  78. Designing Consciousness: Psychedelics as Ontological Design Tools for Decolonizing Consciousness
    Joshua Falcon · 2020 · Design and Culture
  79. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances
    John L. Havlik, Taeho Greg Rhee, Robert Alan Rosenheck · 2024 · PLoS ONE
  80. Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
    Baeleigh VanderZwaag, Albert Garcia‐Romeu, Mauricio A. García-Barrera · 2024 · Therapeutic Advances in Psychopharmacology
  81. Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey
    Jack Stroud, Charlotte Rice, A Orsini, Marco Schlosser, Justine Lee, William Mandy, Sunjeev K. Kamboj · 2024 · Psychopharmacology
  82. Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
    Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz, Kacper Łukasiewicz · 2025 · Neuropharmacology
  83. Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases
    Monika Fryc, Daria Kluzik, Anna Czopek, Jakub Jończyk, Agnieszka Zagórska · 2025 · Neuropharmacology
  84. Synaptic priming: A framework for pharmacotherapy in depression
    Kyle A. Brown, Musa Iyiola Ajibola, Gustavo C. Medeiros, Todd D. Gould · 2025 · Neuron
  85. Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
    Cui Guo, Nguyen N T Luu, Maryem M Adwer, Hemen Hosseinzadeh, Venkatesh Balan, Yajun Yan, Yuheng Lin · 2025 · Metabolic Engineering
  86. Recreation and Realization: Reported Motivations of Use Among Persons Who Consume Psychedelics in Non-Clinical Settings
    Cindy Brooks Dollar · 2021
  87. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice
    Gabriella Gobbi, Antonio Inserra, Kyle T. Greenway, Michael Lifshitz, Laurence J. Kirmayer · 2022 · Transcultural Psychiatry
  88. Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists
    E. M. Rørsted, Anders A. Jensen, G. Šmits, K. Frydenvang, Jesper L. Kristensen · 2024 · Journal of Medicinal Chemistry
  89. Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
    Noah Chisamore, Erica S. Kaczmarek, Gia Han Le, Sabrina Wong, Diana K. Orsini, Rodrigo Barbachan Mansur, Roger S. McIntyre, Joshua Daniel Rosenblat · 2024 · Current Treatment Options in Psychiatry
  90. A role for enhanced functions of sleep in psychedelic therapy?
    Tom Froese, Iwin Leenen, Tomáš Páleníček · 2018 · Adaptive Behavior
  91. Attitudes of European psychiatrists on psychedelics: a qualitative study
    Marija Franka Žuljević, Nando Breški, Mariano Kaliterna, Darko Hren · 2024 · Frontiers in Psychiatry
  92. Developmental changes in brain structure and function following exposure to oral LSD during adolescence
    Lila Harris-Blum, Zachary Smith, Richard J. Ortiz, Deepti Athreya, Arnold Chang, Praveen P. Kulkarni, Craig F. Ferris · 2024 · Scientific Reports
  93. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
    Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J Cooper, John Gordon, Catherine Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews et al. · 2025 · British Journal of Pharmacology
  94. Microbiome: The Next Frontier in Psychedelic Renaissance
    Robert B. Kargbo · 2023 · Journal of Xenobiotics
  95. Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics
    Maha N. Mian, Brianna R. Altman, Fiona Low, Mitch Earleywine · 2023 · Journal of Psychopharmacology
  96. Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
    Hugo Bottemanne, Antoine Baldacci, C. Muller, A. Boyreau, Anne Claret · 2021 · L Encéphale
  97. Recent advances in the psychopharmacology of major depressive disorder
    Laith Alexander, Allan Hunter Young · 2022 · BJPsych Advances
  98. Self-administration of Psilocybin in the Setting of Treatment-resistant Depression.
    Ashley Lyons · 2022 · PubMed Central
  99. The effects of serotonergic psychedelics in synaptic and intrinsic properties of neurons in layer II/III of the orbitofrontal cortex
    Zi-Hang Tang, Zhipeng Yu, Qiong Li, Xiaoqin Zhang, Kadeliya Muhetaer, Zhengchun Wang, Peng Xu, Haowei Shen · 2023 · Psychopharmacology
  100. A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history
    Eric N. Kramer, Kalyn Reddy, Bryan B. Shapiro · 2023 · Psychiatry Research Case Reports